secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medicus Pharma Ltd. (MDCX)
CIK:        0001997296
Form:       8-K
Filed at:   2025-08-22T23:59:59+00:00
Accession:  0001062993-25-014806
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medicus Pharma: FDA accepts Type C meeting; Phase 2 BCC study >75% randomized; Q2 net loss $6.2M
--------------------------------------------------------------------------------

- FDA accepted Type C meeting request; written queries submitted, response expected before end of Q3 2025.
- Phase 2 SKNJCT-003 randomized >75% of 90 participants; interim analysis showed >60% clinical clearance.
- Cash $9.7M at Q2-end, up from $4.0M Q1; raised $11.5M net from financings and warrant exercises.
- Q2 net loss $6.2M vs $3.6M YoY; operating expenses $6.0M vs $3.6M YoY.
- CFO James Quinlan exercised 145,000 stock options for ~$156,250 in proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325014806/0001062993-25-014806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325014806/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-25-014806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer